MB
CNTX icon

MPM BioImpact’s Context Therapeutics CNTX Stock Holding History

MPM BioImpact’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28M Hold
10,679,391
– – 2.16% 18
2025
Q4 		$15.7M Sell
10,679,391
-4,026,491
-27% -$4.7M 1.8% 26
2025
Q3 		$14.2M Hold
14,705,882
– – 2.33% 20
2025
Q2 		$9.64M Hold
14,705,882
– – 1.67% 28
2025
Q1 		$9M Hold
14,705,882
– – 1.55% 30
2024
Q4 		$15.4M Buy
+14,705,882
New +$25.4M 2.19% 18

Other funds holding CNTX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

MPM BioImpact's CNTX Position: Q1 2026 in Review

MPM BioImpact held its Context Therapeutics (CNTX) position steady in Q1 2026 at 10,679,391 shares worth $28M. The position accounts for 2.16% of the portfolio, ranked #18.

MPM BioImpact first reported a position in CNTX in Q4 2024 and has held it in 6 quarters since. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • MPM BioImpact held 10,679,391 shares of Context Therapeutics worth $28M as of Q1 2026.
  • MPM BioImpact left its Context Therapeutics share count unchanged in Q1 2026.
  • Context Therapeutics made up 2.16% of MPM BioImpact's portfolio in Q1 2026, its #18 holding.
  • MPM BioImpact first reported a position in Context Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on MPM BioImpact's 13F filing for Q1 2026, filed 15 May 2026.